Biomarkers and Precision Medicine in Upper Gastrointestinal Malignancies

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 1074

Special Issue Editor

Department of Oncology, Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark
Interests: immune-oncology; upper gastro-intestinal cancers; hepato-biliary cancers; pancreas cancer; esophagus cancer; gastric cancer; neuro-endocrine tumors; rare cancers; histopathology; precision medicine; targeted treatments; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The current treatment of patients with upper gastrointestinal cancers is centred around chemotherapy and surgery, with a limited number of patients being candidates for immunotherapy or molecularly targeted treatment based on biomarker selection. The poor efficacy of treatment, late diagnoses, and the aggressive behavior of most cases contribute to the high mortality of these diseases.

To improve results, one major approach pursues the stratification of patients, according to the molecular characteristics for predicting treatment responses or resistance. Other strategies focus on novel biomarkers for early diagnosis, the detection of progression or relapse, or prognosis.

We invite researchers to publish studies within this topic in upper gastrointestinal malignancies, including esophageal-gastric, pancreatic, duodenal/small bowel, and hepatic–biliary cancers.

I look forward to receiving your contributions.

Prof. Dr. Morten Ladekarl
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • molecular biology
  • biomarker
  • prognosis
  • diagnosis
  • esophagus cancer
  • gastric cancer
  • pancreatic cancer
  • hepatocellular carcinoma
  • cholangiocarcinoma
  • duodenal cancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

9 pages, 375 KiB  
Review
Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma
Curr. Oncol. 2024, 31(2), 769-777; https://doi.org/10.3390/curroncol31020057 - 01 Feb 2024
Viewed by 829
Abstract
Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor receptor-2 (HER-2) represented the [...] Read more.
Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor receptor-2 (HER-2) represented the single target in GACs for many years, seen in approximately 20% of patients with advanced GAC. Recent advances in management now include the addition of immunotherapy checkpoint inhibition to select front-line advanced GACs. Unfortunately, outcomes remain poor for most patients. We anticipate finding a key to future discoveries in GACs in next-generation sequencing and more targeted approaches. Claudin 18.2 (CLDN18.2) has emerged as a therapeutic target in GACs. CLDN18.2 is reportedly expressed in 14–87% of GACs, and CLDN18.2 is available for monoclonal antibody (mAb) binding as it is expressed on the outer cell membrane. Here, we review the exploration of CLDN18.2 as a target in GACs via the use of zolbetuximab (IMAB362). Zolbetuximab is now under priority FDA review for GACs, and we eagerly await the review outcome. Full article
Show Figures

Figure 1

Back to TopTop